Literature DB >> 35192785

Care pathways in invasive meningococcal disease: a retrospective analysis of the French national public health insurance database.

Catherine Weil-Olivier1, Muhamed-Kheir Taha2, Stéphane Bouée3, Corinne Emery3, Véronique Loncle-Provot4, Gaëlle Nachbaur4, Ekkehard Beck5, Céline Pribil4.   

Abstract

Invasive meningococcal disease (IMD) carries a high burden in terms of mortality, long-term complications, and cost, which can be significantly reduced by vaccination. The objectives of this case-control study were to document the care pathways of patients with IMD before, during, and after hospitalization and to assess in-hospital complications and long-term sequelae. Cases consisted of all people hospitalized for IMD in France between 2012 and 2017. Controls were matched by age, gender, and district of residence. Data were extracted from the French national public health insurance database on demographics, hospitalizations, mortality and potential sequelae of IMD. Overall, 3,532 cases and 10,590 controls were assessed and followed up for 2.8 years (median). During hospitalization, 1,577 cases (44.6%) stayed in an intensive care unit, 1,238 (35.1%) required mechanical ventilation, and 43 (1.2%) underwent amputation; 293 cases (8.3%) died in hospital and a further 163 (4.6%) died following discharge; 823 cases (25.4% of survivors) presented ≥1 sequela and 298 (9.2%) presented multiple sequelae. The most frequently documented sequelae were epilepsy (N = 205; 5.8%), anxiety (N = 196; 5.5%), and severe neurological disorders (N = 193; 5.5%). All individual sequelae were significantly more frequent (p < .0001) in cases than controls. Hearing/visual impairment and communication problems were conditions that presented the highest risk for cases compared to controls (risk ratios >20 in all cases). In conclusion, this study highlights the importance of providing optimal medical care for patients with IMD, of minimizing the delay before hospitalization, and of effective prevention through comprehensive vaccination programs.

Entities:  

Keywords:  France; Invasive meningococcal disease; care pathways; health insurance database; mortality; sequelae

Mesh:

Substances:

Year:  2022        PMID: 35192785      PMCID: PMC8993105          DOI: 10.1080/21645515.2021.2021764

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  50 in total

1.  Socioeconomic inequality and meningococcal disease.

Authors:  J M Stuart; N Middleton; D J Gunnell
Journal:  Commun Dis Public Health       Date:  2002-12

2.  Acute bacterial meningitis in adults. A 20-year overview.

Authors:  B Sigurdardóttir; O M Björnsson; K E Jónsdóttir; H Erlendsdóttir; S Gudmundsson
Journal:  Arch Intern Med       Date:  1997-02-24

3.  Characteristics and changes in invasive meningococcal disease epidemiology in France, 2006-2015.

Authors:  I Parent du Chatelet; A E Deghmane; D Antona; E Hong; L Fonteneau; M K Taha; D Lévy-Bruhl
Journal:  J Infect       Date:  2017-03-07       Impact factor: 6.072

4.  Epidemiology, clinical presentation, risk factors, intensive care admission and outcomes of invasive meningococcal disease in England, 2010-2015.

Authors:  Sydel R Parikh; Helen Campbell; Stephen J Gray; Kazim Beebeejaun; Sonia Ribeiro; Ray Borrow; Mary E Ramsay; Shamez N Ladhani
Journal:  Vaccine       Date:  2018-04-24       Impact factor: 3.641

5.  Strains Responsible for Invasive Meningococcal Disease in Patients With Terminal Complement Pathway Deficiencies.

Authors:  Jérémie Rosain; Eva Hong; Claire Fieschi; Paula Vieira Martins; Carine El Sissy; Ala-Eddine Deghmane; Marie Ouachée; Caroline Thomas; David Launay; Loïc de Pontual; Felipe Suarez; Despina Moshous; Capucine Picard; Muhamed-Kheir Taha; Véronique Frémeaux-Bacchi
Journal:  J Infect Dis       Date:  2017-04-15       Impact factor: 5.226

6.  Hospital admissions for meningococcal infection in Spain (1997-2005).

Authors:  J M San Roman Montero; R Gil Prieto; C Gomez Alejandre; L Alvaro Meca; P Portugal; A Gil de Miguel
Journal:  J Infect       Date:  2008-11-30       Impact factor: 6.072

7.  Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study.

Authors:  Russell M Viner; Robert Booy; Helen Johnson; W John Edmunds; Lee Hudson; Helen Bedford; Ed Kaczmarski; Kaukab Rajput; Mary Ramsay; Deborah Christie
Journal:  Lancet Neurol       Date:  2012-08-03       Impact factor: 44.182

8.  Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.

Authors:  Héloïse Lecocq; Isabelle Parent du Châtelet; Muhamed-Kheir Taha; Daniel Lévy-Bruhl; Benoit Dervaux
Journal:  Vaccine       Date:  2016-03-19       Impact factor: 3.641

9.  Recurrent invasive meningococcal infections - quantifying the risk, Germany, 2002 to 2018.

Authors:  Manuel Krone; Thiên-Trí Lâm; Heike Claus; Ulrich Vogel
Journal:  Euro Surveill       Date:  2020-06

10.  Clinical and economic burden of invasive meningococcal disease: Evidence from a large German claims database.

Authors:  Liping Huang; Olivia Denise Heuer; Sabrina Janßen; Dennis Häckl; Niklas Schmedt
Journal:  PLoS One       Date:  2020-01-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.